Add like
Add dislike
Add to saved papers

Knocking Down lncRNA HOXA-AS2 Mitigates the Progression of Epilepsy via Regulation of the miR-372-3p/STAT3 Axis.

Turkish Neurosurgery 2022 September 13
AIM: The purposes of current research are to explore the potential activity of HOXA-AS2, a lncRNA (long non-coding RNA), in epilepsy progression, as well as the mechanisms behind its activity.

MATERIAL AND METHODS: Kainic acid (KA) was used to treat CTX-TNA2 cells (rat astroglial cells) as a cellular model of epilepsy. The qRT-PCR (quantitative reverse transcription-polymerase chain reaction) was conducted to examine the expressions levels of HOXA-AS2, miR-372-3p, as well as STAT3. Meanwhile, a combination of CCK (Cell Counting Kit)-8, flow cytometry and WB (Western-blot) were performed, in order to analyze cell viability and apoptosis, respectively. Further, the secretion levels of various inflammatory factors (IL-6, IL-1β, and TNF-α) were identified by ELISA. Besides, with the aim of validating the functional interaction between HOXA-AS2/STAT3 with miR‑372-3p, a reporter assay (dual-luciferase) was performed.

RESULTS: HOXA-AS2 and STAT3 expression levels were notably upregulated, whereas miR‑372-3p was downregulated in KA-treated CTX-TNA2 cells. Silencing HOXA-AS2 or overexpressing miR-372-3p inhibited the inflammatory factor secretions and cell apoptosis in KA-treated CTX-TNA2 cells. This study further showed that HOXA-AS2 negatively regulated miR‑372-3p, and miR‑372-3p targeted STAT3 mRNA. The suppression of miR-372-3p or excessive expression of STAT3 abrogated the rescue effect of si-HOXA-AS2 in KA-treated CTX-TNA2 cells.

CONCLUSION: Our study suggests that targeting HOXA-AS2 could alleviate cellular damages in the epileptic model by regulating miR-372-3p/STAT3 axis. Therefore, HOXA-AS2 might play the role of a potential anti-epilepsy therapeutic target.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app